Promising results of preclinical studies evaluating the effectiveness of SYGN113 to treat bacterial biofilms in the lungs of patients with cystic…
Articles by Joana Fernandes, PhD
Results of the safety, stability, and effectiveness of Spyryx Biosciences‘ drug candidate SPX-101 for cystic fibrosis (CF) will be presented…
A new device using Bluetooth technology, called eRapid, can administer inhaled therapies to patients with cystic fibrosis (CF) and…
The U.S. Food and Drug Administration (FDA) approved a new dose of Pertzye (pancrelipase) to specifically treat infants (up to…
A preclinical study using animal models of cystic fibrosis (CF) showed that SPX-101, a treatment being developed by Spyryx Biosciences, effectively cleared…
Treating patients with cystic fibrosis (CF) or chronic obstructive pulmonary disease (COPD), infected with the fungus Aspergillus fumigatus, with antifungal therapies may…
Results of a clinical trial evaluating Resunab (JBT-101) in a model of inflammation in healthy subjects indicated that this drug may…
Certain molecules present in the sputum — “coughed-up” material from the trachea and lungs — can help to predict the onset…
Two studies published in the Journal of Clinical Investigation (JCI) demonstrate the potential of pigs with cystic fibrosis (CF)…
A new study published in the journal Science Advances sheds light on the molecular mechanisms responsible for the pathology…